Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Anjuli Nayak, Niroo Gupta(Teleflex (United States)), Giovanni Della Cioppa(Asahi Glass (Belgium)), John J. Condemi(Baylor College of Medicine), Margaret McAlary, Angel FowlerTaylor(Novartis (United States)), Thomas B. Casale(University of South Florida), S. David Miller(Southern General Hospital)
PubMed
March 25, 2004
Cited by 45
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k